Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 15/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23122830 | 0.80 | MAP3K12 (0.38) | MAP3K12MTORPIK3CAPRKDCMAP3K13 | |
| SCHEMBL29745241 | 0.80 | MAP3K12 (0.38) | MAP3K12MTORPIK3CAPRKDCMAP3K13 | |
| SCHEMBL23122900 | 0.72 | DRD2 (0.43) | MAP3K12PDE10A | |
| SCHEMBL23123423 | 0.72 | CHRNA7 (0.44) | — | |
| SCHEMBL29745052 | 0.72 | CHRNA7 (0.44) | — | |
| SCHEMBL23123138 | 0.72 | CHRNA7 (0.44) | — | |
| SCHEMBL23122838 | 0.72 | CHRNA7 (0.44) | — | |
| SCHEMBL22163205 | 0.72 | MAP3K12 (0.51) | MAP3K12MTORPIK3CAMAP3K13PDE10A | |
| SCHEMBL15399039 | 0.71 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAPRKDCMAP3K13 | |
| SCHEMBL17076880 | 0.71 | MAPT (0.42) | MAP3K12MTORPIK3CAMAP3K13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | MAP3K12 2505/4885MTOR 918/4885PIK3CA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.